Skip to main content

Alaunos Therapeutics, Inc.

corporate_fare Company Profile

Alaunos Therapeutics, Inc.

TCRT·NASDAQ·Life Sciences·CIK 0001107421

Alnara Therapeutics is a preclinical-stage biopharmaceutical company developing new, orally administered small-molecule treatments for obesity and related metabolic disorders, including metabolic dysfunction-associated steatotic liver disease (MASLD). The company's approach is non-hormonal and non-incretin, differing from hormone-based treatments like GLP-1 drugs. On March 2, 2026, Alnara Therapeutics announced positive preclinical proof-of-concept data for ALN1003 from two studies using a standard diet-induced obesity (DIO) mouse model in male C57BL/6 mice on a high-fat diet (60% of calories from fat). These studies showed dose-dependent body weight loss with favorable body composition changes, reductions in liver weight, and improvements in liver function and metabolic biomarkers. Alnara Therapeutics was previously a clinical-stage oncology-focused cell therapy company. The company has not generated any product revenue and has incurred significant net losses since its inception, reporting a net loss of $4.2 million for the year ended December 31, 2025, and an accumulated deficit of $924.6 million as of that date. The small molecule oral obesity and metabolic disorders program is internally developed and focuses on discovering and developing novel, orally administered therapeutics with a non-hormonal mechanism of action, distinct from other pipeline therapies exploring hormonal pathways such as amylin or dual GIP/GLP-1 receptor agonism.

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for TCRT at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Alaunos Therapeutics Faces Imminent Liquidity Crisis and Heightened Delisting Risk as Cash Dwindles to $0.35M
  • Alaunos Therapeutics Receives Formal Nasdaq Delisting Notice for Equity Deficiency
  • Alaunos Therapeutics Discloses Going Concern Doubt, Nasdaq Delisting Risk, and Short Cash Runway
  • Alaunos' Oral Obesity Drug ALN1003 Shows Positive Preclinical Proof-of-Concept Data
  • Alaunos Therapeutics Reports Positive Preclinical Data for Obesity Drug ALN1003 Amidst Urgent Financing Needs

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$5K
Net Income
-$4.18M
Diluted EPS
-$2.20
Op. Cash Flow
-$2.87M
Free Cash Flow
-$2.97M
Operating Income
-$4.22M
Cash & Equivalents
$1.39M
Debt / Equity
0.00×
Net Margin
-835.20×
Shares Outstanding
2.35M sh
Source: 10-K · filed 2026-04-30 · accession 0001193125-26-197838
$1.66
52-week range · as of 2026-11-16 $0.719 – $4.5
Market cap
$6.99M
Volume
77.5K (0.0× avg)
3-mo avg 14.4M
Live data · 2026-11-22 13:02 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TCRT - Filings & News (Page 2)

TCRT
May 15, 2026, 5:29 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.47
Real-time Price: $1.66 info
Change: -$0.810 (-33%) info
Market Cap: $6.986M info
TCRT
Apr 15, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.89
Real-time Price: $1.66 info
Change: -$1.23 (-43%) info
Market Cap: $6.986M info
TCRT
Mar 31, 2026, 4:33 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.86
Real-time Price: $1.66 info
Change: -$1.20 (-42%) info
Market Cap: $6.986M info
TCRT
Mar 02, 2026, 9:13 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $3.01
Real-time Price: $1.66 info
Change: -$1.35 (-45%) info
Market Cap: $6.986M info
TCRT
Mar 02, 2026, 6:29 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.18
Real-time Price: $1.66 info
Change: -$1.52 (-48%) info
Market Cap: $6.986M info
TCRT
Feb 24, 2026, 4:56 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $2.85
Real-time Price: $1.66 info
Change: -$1.19 (-42%) info
Market Cap: $6.986M info
TCRT
Jan 08, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.31
Real-time Price: $1.66 info
Change: -$1.65 (-50%) info
Market Cap: $6.986M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets